4.85k followers • 31 symbols Watchlist by Yahoo Finance
Follow this list to discover and track large drug and biotechnology companies.
Curated by Yahoo Finance
Follow this list to discover and track large drug and biotechnology companies. These companies develop specialty drugs and treatments for various diseases and medical conditions. Although there are risks associated with the success of the drug, those that succeed tend to have a strong series of earnings growth over a period of time, especially when they are backed by patents.
The list includes stocks priced at $5 or more with a three month average daily trading volume in excess of 200,000 shares. This list is generated daily and sorted by market cap; the gains are based on the latest closing price and limited to the top 30 stocks that meet the criteria.
This watchlist is similar to a discontinued watchlist called Battling Cancer.
Yahoo Finance employs sophisticated algorithms to monitor and detect trends in the Global Financial Markets. We bring these insights to you in the form of watchlists.
Find other winning investment ideas with the Yahoo Finance Screener.How are these weighted?
The stocks in this watchlist are weighted equally.
|Watchlist||Change Today||1 Month Return||1 Year Return||Total Return|
|Biotech and Drug Stocks||+0.32%||-||-||-|
|Symbol||Company Name||Last Price||Change||% Change||Market Time||Volume||Avg Vol (3 month)||Market Cap|
|JNJ||Johnson & Johnson||165.22||-0.20||-0.12%||4:00 p.m. EDT||5.67M||5.93M||435.09B|
|RHHBY||Roche Holding AG||46.82||-0.04||-0.09%||4:00 p.m. EDT||506.03k||1.08M||325.63B|
|PFE||Pfizer Inc.||44.47||-0.30||-0.67%||4:02 p.m. EDT||21.96M||31.64M||248.93B|
|NVO||Novo Nordisk A/S||102.38||+1.11||+1.10%||4:00 p.m. EDT||955.59k||997.05k||236.74B|
|LLY||Eli Lilly and Company||231.04||-2.69||-1.15%||4:02 p.m. EDT||2.66M||2.73M||221.57B|
|ABBV||AbbVie Inc.||108.08||+0.31||+0.29%||4:02 p.m. EDT||5.67M||6.88M||190.89B|
|NVS||Novartis AG||84.38||-0.70||-0.82%||4:00 p.m. EDT||1.85M||1.73M||189.96B|
|MRK||Merck & Co., Inc.||71.97||-0.84||-1.15%||4:02 p.m. EDT||13.11M||9.90M||182.23B|
|MRNA||Moderna, Inc.||440.65||+6.19||+1.42%||4:00 p.m. EDT||10.11M||17.94M||176.93B|
|AZN||AstraZeneca PLC||56.6||+0.15||+0.27%||4:00 p.m. EDT||5.11M||10.11M||149.22B|
|BMY||Bristol-Myers Squibb Company||61.23||-0.77||-1.24%||4:00 p.m. EDT||13.59M||8.43M||138.14B|
|AMGN||Amgen Inc.||217.36||-0.77||-0.35%||4:00 p.m. EDT||2.70M||2.38M||124.89B|
|SNY||Sanofi||48.19||+0.18||+0.37%||4:00 p.m. EDT||1.06M||1.95M||120.55B|
|GSK||GlaxoSmithKline plc||39.11||-0.11||-0.28%||4:00 p.m. EDT||1.88M||4.00M||98.39B|
|ZTS||Zoetis Inc.||202.77||-1.19||-0.58%||4:03 p.m. EDT||1.46M||1.50M||96.27B|
|BNTX||BioNTech SE||372.65||+17.40||+4.90%||4:00 p.m. EDT||4.61M||4.04M||90.00B|
|GILD||Gilead Sciences, Inc.||71.33||-0.43||-0.60%||4:00 p.m. EDT||5.16M||6.10M||89.46B|
|REGN||Regeneron Pharmaceuticals, Inc.||653.18||+1.18||+0.18%||4:00 p.m. EDT||505.67k||784.79k||69.59B|
|TAK||Takeda Pharmaceutical Company Limited||17.2||+0.20||+1.18%||4:00 p.m. EDT||2.28M||1.76M||54.38B|
|BAYRY||Bayer Aktiengesellschaft||13.48||+0.02||+0.15%||3:59 p.m. EDT||589.79k||435.31k||52.97B|
|VRTX||Vertex Pharmaceuticals Incorporated||187.1||-1.76||-0.93%||4:00 p.m. EDT||1.55M||2.08M||48.43B|
|BIIB||Biogen Inc.||299.69||+0.48||+0.16%||4:00 p.m. EDT||726.66k||1.28M||45.12B|
|BGNE||BeiGene, Ltd.||385.24||+9.91||+2.64%||4:00 p.m. EDT||393.05k||338.14k||35.53B|
|SGEN||Seagen Inc.||153.57||+1.48||+0.97%||4:00 p.m. EDT||464.82k||704.31k||27.87B|
|GMAB||Genmab A/S||42.28||-0.58||-1.35%||4:00 p.m. EDT||460.71k||479.74k||27.63B|
|HZNP||Horizon Therapeutics Public Limited Company||107.95||+1.88||+1.77%||4:00 p.m. EDT||989.75k||1.30M||24.19B|
|CTLT||Catalent, Inc.||138.17||-0.09||-0.07%||4:02 p.m. EDT||1.61M||791.85k||23.54B|
|RPRX||Royalty Pharma plc||38.38||+0.41||+1.08%||4:00 p.m. EDT||3.15M||2.40M||23.30B|
|ALNY||Alnylam Pharmaceuticals, Inc.||190.2||+2.72||+1.45%||4:00 p.m. EDT||320.57k||652.07k||22.36B|
|TECH||Bio-Techne Corporation||529.46||-0.18||-0.03%||4:00 p.m. EDT||151.03k||330.22k||20.59B|
Dr. Jabraan Pasha, internal medicine physician at University of Oklahoma Medical Center in Tulsa, joins the Yahoo Finance Live panel to discuss the latest COVID-19 developments
A British study will look into the immune responses of children to mixed schedules of different COVID-19 vaccines as officials try to determine the best approach to second doses in adolescents given a small risk of heart inflammation. Children aged 12-15 in Britain will be vaccinated from next week, while those aged 16-17 have been eligible for shots since August. However, while the children will be offered a first dose of the Pfizer-BioNTech vaccine, officials have said that advice about second doses will be given at a later date, while more data is gathered.
New quality of life data for 177Lu-PSMA-617 plus standard of care shows delay in worsening of health-related quality of life (HRQoL) and pain in heavily pre-treated patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) compared to standard of care alone1 US Food and Drug Administration (FDA) granted Breakthrough Therapy designation to 177Lu-PSMA-617; Submission to FDA and European Medicines Agency on track for 2H21 Novartis committed to reimagining prostate cancer w